Investigational Drug Information for Tideglusib
✉ Email this page to a colleague
What is the development status for investigational drug Tideglusib?
Tideglusib is an investigational drug.
There have been 9 clinical trials for Tideglusib.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 23rd 2021.
The most common disease conditions in clinical trials are Myotonic Dystrophy, Alzheimer Disease, and Amyotrophic Lateral Sclerosis. The leading clinical trial sponsors are AMO Pharma Limited, Noscira SA, and University of Western Ontario, Canada.
There are one hundred and fifty US patents protecting this investigational drug and one hundred and seventy-six international patents.
Summary for Tideglusib
| US Patents | 150 |
| International Patents | 176 |
| US Patent Applications | 460 |
| WIPO Patent Applications | 201 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 2 (2021-08-23) |
| Vendors | 65 |
Recent Clinical Trials for Tideglusib
| Title | Sponsor | Phase |
|---|---|---|
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | AMO Pharma | Phase 2 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | Canadian SADS | Phase 2 |
Clinical Trial Summary for Tideglusib
Top disease conditions for Tideglusib
Top clinical trial sponsors for Tideglusib
US Patents for Tideglusib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tideglusib | ⤷ Start Trial | .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof | Quadriga Biosciences, Inc. (Los Altos, CA) | ⤷ Start Trial |
| Tideglusib | ⤷ Start Trial | Compositions and methods for treating cancers | CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) | ⤷ Start Trial |
| Tideglusib | ⤷ Start Trial | Reprogramming fibroblasts into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (San Francisco, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tideglusib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tideglusib | Argentina | AR105592 | 2035-08-03 | ⤷ Start Trial |
| Tideglusib | Australia | AU2016302243 | 2035-08-03 | ⤷ Start Trial |
| Tideglusib | Canada | CA2994404 | 2035-08-03 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
